Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab

Journal of Neuropathology and Experimental Neurology

Volumn 71, Issue 7, 2012, Pages 604-617

  Kleinschmidt Demasters, B K ^a   Miravalle, Augusto ^a   Schowinsky, Jeffrey ^a   Corboy, John ^a   Vollmer, Timothy ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; MEFLOQUINE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MIRTAZAPINE; MYELIN BASIC PROTEIN; NATALIZUMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ATAXIC APHASIA; B LYMPHOCYTE; CASE REPORT; CELL INFILTRATION; CEREBROSPINAL FLUID; COUGHING; CROHN DISEASE; CYTOMEGALOVIRUS; DISEASE ACTIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE REARRANGEMENT; GLIOSIS; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MORTALITY; MULTIPLE SCLEROSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAPLEGIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHINORRHEA; SURVIVAL RATE; T CELL LYMPHOMA; T LYMPHOCYTE; UNITED STATES; VIRUS INFECTION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGIC FACTORS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 84862861720     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31825caf2c     Document Type: Review

References (47)

1. Berger JR, Houff S. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol 2009;65:367-77
2. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69:292-302
3. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
4. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74 (Pubitemid 41132341)
5. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353:375-81 (Pubitemid 41132342)
6. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8 (Pubitemid 41132340)
7. BiogenIdec: https://medinfo.biogenidec.com. 2012. Accessed May 30, 2012.
8. Phan-Ba R, Lommers E, Tshibanda L, et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 2012;83:224-6
9. Blair NF, Brew BJ, Halpern JP. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology 2012; 78:507-8
10. Ayzenberg I, Lukas C, Trampe N, et al. Value of MRI as a surrogate marker for PML in natalizumab long-term therapy. J Neurol 2012; [Epub ahead of print]
11. Bergamaschi R, Montomoli C. Melanoma in multiple sclerosis treated with natalizumab: Causal association or coincidence? Mult Scler 2009; 15:1532-3
12. Ismail A, Kemp J, Sharrack B. Melanoma complicating treatment with natalizumab (Tysabri) for multiple sclerosis. J Neurol 2009;256: 1771-2
13. Laroni A, Bedognetti M, Uccelli A, et al. Association of melanoma and natalizumab therapy in the Italian MS population: A second case report. Neurol Sci 2011;32:181-2
14. Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 2008;358: 647-8 (Pubitemid 351214309)
15. Panzara MA, Bozic C, Sandrock AW. More on melanoma with transdifferentiation. N Engl J Med 2008;359:99; [author reply-100] (Pubitemid 351931122)
16. Schweikert A, Kremer M, Ringel F, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009;66:403-6
17. Vavricka BM, Baumberger P, Russmann S, et al. Diagnosis of melanoma under concomitant natalizumab therapy. Mult Scler 2011;17:255-6
18. Zecca C, Nessi F, Bernasconi E, et al. Ocular toxoplasmosis during natalizumab treatment. Neurology 2009;73:1418-9
19. Stuve O, Wiendl H. Iatrogenic immunosuppression with biologics in MS: Expecting the unexpected? Neurology 2009;73:1346-7
20. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: Emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213-27 (Pubitemid 34507208)
21. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005;19:399-406 (Pubitemid 40446186)
22. Rushing EJ, Liappis A, Smirniotopoulos JD, et al Immune reconstitution inflammatory syndrome of the brain: Case illustrations of a challenging entity. J Neuropathol Exp Neurol 2008;67:819-27
23. Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011; 77:1061-7
24. Perumal J, Hreha S, Bao F, et al. Post-natalizumab associated rebound or CNS immune reconstituion syndrome: Clinical and MRI findings. Mult Scler 2009;15:S119
25. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011;68:186-91
26. Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008;70:1150-1 (Pubitemid 351464749)
27. Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol 2011;24:284-90
28. Lindberg RL, Achtnichts L, Hoffmann F, et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008;194:153-64
29. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases. Lancet Neurol 2010;9:438-46
30. Langford TD, Letendre SL, Marcotte TD, et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 2002;16:1019-29 (Pubitemid 34499425)
31. Schwab N, Hohn KG, Schneider-Hohendorf T, et al. Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler 2012;18:335-44
32. Lenhard T, Biller A, Mueller W, et al. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 2010;75:831-3
33. Metz I, Radue EW, Oterino A, et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 2012;123: 235-45
34. Swerdlow SH, Campo E, Harris NL, et al, ed. WHO Classification of Tumours of Haematopoietic and Lymphoic tissues, Fourth Ediciton. Lyon: IARC, 2008;417
35. Schowinsky J, Corboy J, Vollmer T, et al. Natalizumab-associated complication? First case of peripheral T-cell lymphoma. Acta Neuropathol 2012;123:751-2
36. Posnett DN, Sinha R, Kabak S, et al. Clonal populations of T cells in normal elderly humans: The T-cell equivalent to "benign monoclonal gammapathy". J Exp Med 1994;179:609-18
37. Bauer M, Brakebusch C, Coisne C, et al. Beta1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proc Natl Acad Sci USA 2009;106:1920-5
38. Frisullo G, Iorio R, Plantone D, et al. CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment. Mult Scler 2011;17:556-66
39. Ramos-Cejudo J, Oreja-Guevara C, Stark Aroeira L, et al. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism. J Clin Immunol 2011;31:623-31
40. Putzki N, Baranwal MK, Tettenborn B, et al. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol 2010;63:311-7
41. Stenner MP, Waschbisch A, Buck D, et al. Effects of natalizumab treatment on Foxp3+ T regulatory cells. PLoS One 2008;3:e3319
42. Krumbholz M, Meinl I, Kumpfel T, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008;71:1350-4
43. Lesesve JF, Debouverie M, Decarvalho Bittencourt M, et al. CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes. Bone Marrow Transplant 2011;46: 1489-91
44. Leclerc M, Lesesve JF, Gaillard B, et al. Binucleated lymphocytes in patients with multiple sclerosis treated with natalizumab. Leuk Lymphoma 2011;52:910-2
45. Bonig H, Wundes A, Chang KH, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008;111:3439-41
46. West TW, Cree BA. Natalizumab dosage suspension: Are we helping or hurting? Ann Neurol 2008;68:395-9
47. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011;76:1858-65